Please select the option that best describes you:
Would you recommend enfortumab vedotin plus pembrolizumab for localized advanced non-invasive urothelial carcinoma of the renal pelvis?
What factors would you use in your consideration of EV+P in this situation? Would baseline GFR or the risk of HD with nephroureterectomy inform this decision? What else?
Answer from: Medical Oncologist at Community Practice
Urothelial carcinoma of the renal pelvis is always challenging to stage and is often understaged. However, it would be difficult to justify systemic therapy with EV + P for non-invasive disease on the path. This patient will likely need upfront RNU followed by adjuvant therapy based on pathological ...
Sign In or Register to read more